Articles

Allogenic Hematopoietic Stem Cell Transplantation from Related Donors in Fanconi Anemia

Abstract

 Introduction: Allogeneic hematopoietic cell transplantation (HSCT) is the only therapeutic modality capable of correcting the hematologic manifestations of Fanconi Anemia (FA). The development  of well  tolerated,  immunosuppressive  conditioning  regimens  for FA patients  undergoing HSCT has proven to be a rather challenging task for hematologists.
Methods: We analyzed the outcome of 30 FA patients (median age at HSCT was 9 years age range, 2-32 years) who underwent HSCT between 1992 and 2008 in Shariati Hospital Tehran, Iran. . Patients were transplanted from either an HLA-identical sibling or matched relative (n=29), or an HLA-partially matched relative(n=1). Four  different  conditioning  regimens  without  radiation  were  used  .Graft  versus  host  disease  (GVHD) prevention consisted of cyclosporine with methotrexate or cyclosporine alone.
Results: The median follow-up duration for survivors was 2.7 years (ranged 1 month to 12 years). The median survival time was 8.5 months. The 5-year overall surviv l was 43.6% (SE=10.0%). All surviving patients had normal blood counts with full donor engraftment. The median survival rate for patients who did or did not receive fludarabine in preparation for the allograft was not statistically significant (p-value=1.0).
Conclusion: 
Our  study  demonstrates  that  none  of the  studied  variables  significantly  affected  the  survival, including  sex,  age,  radiation-free  conditioning  regimens,  corticosteroids  before  transplant,  pre-transplant transfusions, acute GVHD and congenital abnormalities. The availability of better diagnostic tools to predict clinical course of FA, and modification of the conditioning regimen should improve survival and long-term consequences of therapy for patients in the future.

Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anemia. Nat Rev Genet. 2001;2:446–457.

Auerbach AD, Buchwald M, Joenje H. Fanconi anemia. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd edition. New York: McGraw-Hill, Inc.; 2002. p 289–306.

Giampletro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an International Fanconi Anemia Registry study. Am J Med Genet. 1997;68:58-61.

Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood. 2004;103:2498–2503.

Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nature Genetics. 2005;37:958–963.

Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi’s anemia. Blood. 2003;101:822-826.

Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.

Gluckman E, Auerbach AD, Horowitz MH, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856-2862.

Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.

Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84:1650-1655.

Medeiros C, Zanis-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning Bone Marrow Transplant. 1999;24:849-852.

Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 2000;95:422-429.

de La Fuente J, Reiss S, McCloy M, et al. Non TBI stem cell transplantation protocol for Fanconi anemia using HLA- compatible sibling and unrelated donors. Bone Marrow Transplant. 2004;34:95.

Guardiola P, Socié G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA identical sibling donors: risk factors and influence on outcome. Blood. 2004;103:73-77.

Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.

Lee SJ, Vogelsang G, Flowers MED. Chronic graft- versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.

Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol. 1980;45:565–568.

Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen marrow transplantation. Br J Haematol. 1983;54:431–440.

Gluckman E. Radiosensitivity in Fanconi anemia: application143 to the conditioning for bone marrow transplantation. Radiother Oncol. 1990;18(Suppl. 1):88–93.

Zanis-Neto J, Flowers ME, Medeiros CR, et al. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. Br J Haematol. 2005;130:99-106.

Socie´ G, Henry-Amar M, Cosset JM, et al. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;74:277–275.

Pierga JY, Socie G, Gluckman E et al. Secondary solid malignant tumors occurring after bone marrow transplantation for evere aplastic anemia given thoraco-abdominal irradiations. Radiother Oncol. 1994;30:55–58.

Deeg HJ, Socie´ G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392.

Santos GW, Owens AH Jr. Allogeneic marrow transplants in cyclophosphamide treated mice. Transplant Proc. 1969;1:44-46.

Storb R, Epstein RB, Rudolph RH, Thomas ED. Allogeneic canine bone marrow transplantation following cyclophosphamide. Transplantation. 1969;7:378-386.

Storb R, Buckner CD, Dillingham LA, Thomas ED. Cyclophosphamide regimens in rhesus monkeys with and without marrow infusion. Cancer Res. 1970;30:2195-2203.

Deeg HJ, Storb R, Prentice R, et al. Increased cancer risk in canine radiation chimeras. Blood. 1980;55:233-239.

Witherspoon RP, Storb R, Pepe M, et al. Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone (Letter). Blood. 1992;79:289-292.

Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.

Storb R, Thomas ED, Buckner CD, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974;43:157-180.

Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation for Fanconi anaemia. Br J Haematol. 1980;45:557-564.

Deeg HJ, Storb R, Thomas ED, et al. Fanconi’s anemia treated by allogeneic marrow transplantation. Blood. 1983;61:954-959.

Flowers MED, Zanis J, Pasquini R, et al. Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol. 1996;92:699-706.

Zanis-Neto J, Ribeiro RC, Medeiros C, et al. Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution. Bone Marrow Transplant. 1995;15:293-298.

Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog- containing chemotherapy: harnessing graft versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.

Tan PL, Wagner JE, Auerbach AD, et al. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer. 2006;46:630-636.

Bitan M, Or R, Shapira MY, et al. Fludarabine-Based Reduced Intensity Conditioning for Stem Cell Transplantation of Fanconi Anemia Patients from Fully Matched Related and Unrelated Donors. Biol Blood Marrow Transplant. 2006;12:712-718.

Files
IssueVol 3, No 1 (2009) QRcode
SectionArticles
Keywords
Fanconi anemia Hematopoietic Stem Cell Transplantation

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ghavamzadeh A, Hamidieh AA, Jahani M. Allogenic Hematopoietic Stem Cell Transplantation from Related Donors in Fanconi Anemia. Int J Hematol Oncol Stem Cell Res. 1;3(1):1-6.